Recipients of HibMenCY-TT + DTaP-HBV-IPV were re-randomized ( @:@:@ ) to receive MenACWY-TT at @-@ months and DTaP at @-@ months ; MenACWY-TT co-administered with DTaP at @-@ months ; or HibMenCY-TT at @-@ months and DTaP at @-@ months .